BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines
Authors
Keywords
-
Journal
ONCOGENE
Volume 37, Issue 12, Pages 1576-1593
Publisher
Springer Nature
Online
2018-01-09
DOI
10.1038/s41388-017-0063-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels
- (2017) Chenbo Ding et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
- (2017) Luis J Schwarz et al. JNCI-Journal of the National Cancer Institute
- Targeting BRAF -Mutant Colorectal Cancer: Progress in Combination Strategies
- (2017) Raghav Sundar et al. Cancer Discovery
- Investigating the utility of human melanoma cell lines as tumour models
- (2017) Krista Marie Vincent et al. Oncotarget
- MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
- (2017) Sean Caenepeel et al. Oncotarget
- Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter
- (2017) Branka Radic-Sarikas et al. Scientific Reports
- An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
- (2017) Luis J Schwarz et al. JNCI-Journal of the National Cancer Institute
- Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
- (2016) D. Oddo et al. CANCER RESEARCH
- Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
- (2016) Sebastian Halbach et al. Cell Communication and Signaling
- Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance
- (2016) M. P. Smith et al. CLINICAL CANCER RESEARCH
- Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers
- (2016) Sofie Ellebaek et al. INTERNATIONAL JOURNAL OF CANCER
- Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model
- (2016) S Halbach et al. LEUKEMIA
- Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations
- (2016) W Liu et al. LEUKEMIA
- The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)
- (2016) Andrew M. Kidger et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
- (2016) D. S. Hong et al. Cancer Discovery
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion
- (2015) Dominik Nörz et al. CELLULAR SIGNALLING
- Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface
- (2015) David Bier et al. ChemMedChem
- Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
- (2015) R. Yaeger et al. CLINICAL CANCER RESEARCH
- MicroRNA-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting GAB1 expression
- (2015) Rongpan Bai et al. INTERNATIONAL JOURNAL OF CANCER
- Proteinase-activated Receptor 2 Promotes Cancer Cell Migration through RNA Methylation-mediated Repression of miR-125b
- (2015) Lan Yang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression
- (2015) C Duckworth et al. ONCOGENE
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
- (2015) Enzo Medico et al. Nature Communications
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
- (2015) L. G. Ahronian et al. Cancer Discovery
- Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
- (2015) Luigi Fattore et al. Oncotarget
- PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
- (2015) Anirudh Prahallad et al. Cell Reports
- Clinical Significance of GAB2, a Scaffolding/Docking Protein Acting Downstream of EGFR in Human Colorectal Cancer
- (2014) Tae Matsumura et al. ANNALS OF SURGICAL ONCOLOGY
- BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer
- (2014) Rona Yaeger et al. CANCER
- Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor
- (2014) C. H. Kugel et al. CANCER RESEARCH
- B-Raf Inhibitors Induce Epithelial Differentiation in BRAF-Mutant Colorectal Cancer Cells
- (2014) R. Herr et al. CANCER RESEARCH
- Molecular Pathways: HER3 Targeted Therapy
- (2014) K. Gala et al. CLINICAL CANCER RESEARCH
- Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma
- (2014) K. Connolly et al. Current Oncology
- A comprehensive transcriptional portrait of human cancer cell lines
- (2014) Christiaan Klijn et al. NATURE BIOTECHNOLOGY
- A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention
- (2013) Roland Rad et al. CANCER CELL
- Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
- (2013) Esther Castellano et al. CANCER CELL
- Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
- (2013) Sebastian Halbach et al. Cell Communication and Signaling
- Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
- (2013) Ethan V. Abel et al. JOURNAL OF CLINICAL INVESTIGATION
- Network quantification of EGFR signaling unveils potential for targeted combination therapy
- (2013) B. Klinger et al. Molecular Systems Biology
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas
- (2013) Cristina Montero-Conde et al. Cancer Discovery
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling
- (2012) Michael Röring et al. EMBO JOURNAL
- Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma
- (2012) A. Hoeben et al. INTERNATIONAL JOURNAL OF CANCER
- Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors
- (2012) F U Wöhrle et al. LEUKEMIA
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Functional characterization of cancer-associated Gab1 mutations
- (2012) C Ortiz-Padilla et al. ONCOGENE
- Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition
- (2012) S Cagnol et al. ONCOGENE
- Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
- (2012) A S Little et al. ONCOGENE
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells
- (2011) Y Wang et al. ONCOGENE
- Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells
- (2010) Zhenfeng Zhang et al. CARCINOGENESIS
- Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development
- (2010) Emmy D.G. Fleuren et al. INTERNATIONAL JOURNAL OF CANCER
- Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation
- (2010) Maria Teresa Herrera Abreu et al. MOLECULAR BIOLOGY OF THE CELL
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- E3 ubiquitin ligases in ErbB receptor quantity control
- (2010) Kermit L. Carraway SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Gab2-Mediated Signaling Promotes Melanoma Metastasis
- (2009) Basil Horst et al. AMERICAN JOURNAL OF PATHOLOGY
- Function, regulation and pathological roles of the Gab/DOS docking proteins
- (2009) Franziska U Wöhrle et al. Cell Communication and Signaling
- GAB2 Amplifications Refine Molecular Classification of Melanoma
- (2009) K. A. Chernoff et al. CLINICAL CANCER RESEARCH
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- How to Grb2 a Gab
- (2009) Franziska U. Wöhrle et al. STRUCTURE
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now